tebapivat
tebapivat: developed by 1 company · 2 clinical trials tracked.
tebapivat evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could tebapivat → AGIO affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) Sickle Cell Disease; Myelodysplastic Syndromes | Phase 2 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) Potential treatment of lower-risk myelodysplastic syndrome (… | Phase 2 |
Clinical Trials (2)
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose- Finding, Efficacy, and Safety Study of Tebapivat in Participants With Sickle Cell Disease
Primary endpoint: Percentage of Participants With Hb Response
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes
Primary endpoint: Phase 2a: Proportion of Participants With Hemoglobin (Hb) Response
Frequently asked questions
Who is developing tebapivat?
tebapivat is being developed by AGIOS PHARMACEUTICALS, INC..
How many clinical trials involve tebapivat?
BioSniper tracks 2 clinical trials involving tebapivat.